Nevertheless, further investigation is needed to determine the role of PRC2/EZH2 in thyroid cancer aggressiveness and dedifferentiation by implementing the use of gene-editing techniques, such as CRISPR/Cas9 in the ATC model. The gene discussed is EZH2; the disease is thyroid gland carcinoma.